Physician profile
Richard E Hernandez
NPI 1235104167
$2,240.80
in general payments reported to CMS, 2019-2025
25 companies · $259 in 2025
The $259 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $317 · 2020: $238 · 2021: $207 · 2022: $75.09 · 2023: $528 · 2024: $617 · 2025: $259.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,328 · Education: $76.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,327.65 |
| Education | $76.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $594.56 | 2022-2025 | |
| Janssen Biotech, INC. | $307.82 | 2019-2025 | Stelara, Tremfya |
| Pentax of America, INC. | $168.27 | 2020 | |
| Intercept Pharmaceuticals, INC. | $155.85 | 2019-2023 | Ocaliva |
| Janssen Scientific Affairs, LLC | $121.24 | 2019 | |
| Redhill Biopharma INC. | $121.15 | 2020-2024 | Aemcolo, Talicia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $97.89 | 2019-2021 | |
| Lilly USA, LLC | $97.03 | 2024-2025 | Omvoh |
| Genzyme Corporation | $75.27 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $62.44 | 2024-2025 | Entyvio |
| Ipsen Biopharmaceuticals, INC | $49.88 | 2024-2025 | Iqirvo |
| Abbott Laboratories | $48.56 | 2021 | |
| Gilead Sciences, INC. | $45.98 | 2024 | |
| Pfizer INC. | $39.88 | 2020-2023 | |
| Braintree Laboratories, INC. | $36.91 | 2019-2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $34.00 | 2023-2025 | Ibsrela |
| Ferring Pharmaceuticals INC. | $29.77 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $27.50 | 2025 | Dupixent |
| Aimmune Therapeutics, INC. | $22.41 | 2025 | Zenpep |
| Mallinckrodt Hospital Products INC. | $22.06 | 2023 | Terlivaz |
| Merck Sharp & Dohme LLC | $19.98 | 2024 | Dificid |
| Astrazeneca Pharmaceuticals LP | $19.86 | 2019 | |
| Qol Medical, LLC | $15.17 | 2024 | Sucraid |
| Exact Sciences Corporation | $14.73 | 2025 | The Cologuard Plus Collection Kit |
| Amarin Pharma, INC. | $12.59 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Hernandez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.